Compare CVEO & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CVEO | CHRS |
|---|---|---|
| Founded | 1977 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 297.0M | 296.8M |
| IPO Year | 2013 | 2014 |
| Metric | CVEO | CHRS |
|---|---|---|
| Price | $34.23 | $1.58 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $37.00 | $5.51 |
| AVG Volume (30 Days) | 68.1K | ★ 1.3M |
| Earning Date | 05-01-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 472.00 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.72 | $73.08 |
| Revenue Next Year | $5.61 | $30.94 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $19.75 | $0.72 |
| 52 Week High | $36.50 | $2.62 |
| Indicator | CVEO | CHRS |
|---|---|---|
| Relative Strength Index (RSI) | 67.01 | 39.51 |
| Support Level | $21.32 | $1.55 |
| Resistance Level | $34.80 | $1.80 |
| Average True Range (ATR) | 1.76 | 0.11 |
| MACD | 0.25 | -0.02 |
| Stochastic Oscillator | 64.27 | 1.83 |
Civeo Corp provides hospitality services to the natural resources industry in Canada, Australia. The company provides a full suite of services for guests, including lodging, catering and food service, housekeeping and maintenance at accommodation facilities that the company or its customers own. The company provides services that support the day-to-day operations of these facilities, such as laundry, facility management and maintenance, water and wastewater treatments, power generation, communication systems, security and logistics. The company operates in active oil, metallurgical coal, liquefied natural gas and iron ore-producing regions. The company operates in three reportable business segments Canada, and Australia. It derives maximum revenue from Australia.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.